Global erythropoietin drugs market overview
Technavio’s market research analyst predicts the global erythropoietin drugs market to grow steadily and project an impressive overall revenue of USD 10 billion by 2021. One of the primary drivers for this market is the increase in chronic kidney disease (CKD) and dialysis patient pool.
Get A Free Sample
In terms of geography, EMEA accounted for the maximum market share during 2016 and will continue to dominate the market for the next few years. The market will typically witness a relatively higher growth rate in countries such as the UK, Germany, Spain, France, and Italy. Also, the induction of erythropoietin biosimilars will support the sale of erythropoietin drugs in the region. Moreover, favourable and flexible healthcare regulations in several countries across the globe will further propel the growth of the global erythropoietin drugs market in the coming years.
Erythropoietin drugs market report: Competitive landscape and key vendors
The global erythropoietin drugs market is moderately fragmented due to the presence of international and regional vendors. These vendors exhibit strong R&D capabilities and have established distribution systems in place. Occasional spurts of competition have also been witnessed from the local manufacturers present in various countries. The entry prospect of new players is medium to low, considering the slow growth and complex nature of the market.
Leading vendors in the market are
- F. Hoffmann-La Roche
- Amgen
- Johnson & Johnson
- Kyowa Hakko Kirin
Other prominent vendors in the erythropoietin drugs market include Ahua Pharmaceutical, 3SBio, BIOSIDUS, Biocon, Boehringer Ingelheim, Chugai Pharmaceutical, Celltrion, Intas Pharmaceuticals, Cipla, DAICHI SANKYO, Dr. Reddy's Laboratories, Teva Pharmaceutical Industries, Dragon Pharma, Huaxin High Biotechnology, JCR Pharmaceuticals, Shanghai Kehua Bio-Engineering, LG Life Science, Novartis, Pfizer, Sandoz International, Shenyang Sunshine Pharmaceutical, Shenzhen Sai Bao Er Bio-Pharmaceutical, Sihuan Pharmaceutical, STADA, Uni-Bio Science, and Wanbang Biochemical Pharmaceuticals.
Segmentation by end-users and analysis of the erythropoietin drugs market
- Hospital
- Retail pharmacies
During 2016, the retail pharmacies segment dominated the erythropoietin drugs market and accounted for a major part of the overall market share. The ability of retail pharmacies to provide a large customer base for biosimilars coupled with the requirement from anemic patients for EPO drugs as a maintenance therapy is the key contributor to the dominance of this segment in the global market.
Segmentation by application and analysis of the erythropoietin drugs market
- Renal disease
- Cancer
- HIV
- Wounds and neural disease
Chemotherapy targets fast-dividing cancer cells and the healthy cells in the body. Cells in the bone marrow are highly sensitive to chemotherapy, which results in the decreased production of red blood cells in the body. Erythropoietin binds to the red blood cell progenitor's surface receptor in the bone marrow and stimulates proliferation, maturation, and differentiation of cells. This helps correct anemia in cancer patients.
Want a bigger picture? Try a FREE sample of this report now!
See the complete table of contents and list of exhibits, as well as selected illustrations and example pages from this report.
Key questions answered in the report include
- What will the erythropoietin drugs market size and the growth rate be in 2021?
- What are the key factors driving the global erythropoietin drugs market?
- What are the key erythropoietin drugs market trends impacting the growth of the market?
- What are the challenges to market growth?
- Who are the key vendors in the global erythropoietin drugs market?
- What are the market opportunities and threats faced by the vendors in the global erythropoietin drugs market?
- Trending factors influencing the market shares of the Americas, APAC, and EMEA.
- What are the key outcomes of the five forces analysis of the global erythropoietin drugs market?
Technavio also offers customization on reports based on specific client requirement.
Related reports
Table of Contents
PART 01: Executive summary
PART 02: Scope of the report
- Market overview
- Top-vendor offerings
PART 03: Market research methodology
- Research methodology
- Economic indicators
PART 04: Introduction
PART 05: Biosimilars: Overview
- Comparative analysis of biosimilars and generics
- Biosimilars market opportunities
- Challenges for new entrants
PART 06: Erythropoietin: An overview
- Clinical uses of EPO
- Abusive uses of EPO
- Risks of EPO use
PART 07: Market landscape
- Market overview
- Five forces analysis
PART 08: Pipeline portfolio
- Phase III pipeline portfolio
- Phase II pipeline portfolio
- Phase I pipeline portfolio
- Pre-clinical pipeline portfolio
PART 09: Marketed products portfolio
PART 10: Market segmentation by end-user
- Hospitals
- Retail pharmacies
PART 11: Market segmentation by application
- End-stage renal disease
- Cancer
- HIV
- Wounds and neural disease
PART 12: Market segmentation by product
- First-generation erythropoietin formulation
- Second-generation erythropoietin formulation
- Biosimilars
PART 13: Geographical segmentation
- Erythropoietin drugs market in EMEA
- Erythropoietin drugs market in Europe
- Erythropoietin drugs market in Americas
- Erythropoietin drugs market in US
- Erythropoietin drugs market in APAC
- Erythropoietin drugs market in China
- Erythropoietin drugs market in Japan
- Market overview
PART 14: Market drivers
- Rise in number of patent expiries
- Need for cost-effective treatment
- Increase in CKD and dialysis patient pool
PART 15: Impact of drivers
PART 16: Market challenges
- Physicians' reluctance to prescribe biosimilars
- Multiple manufacturing complexities
- Development of alternative therapies
- Complicated regulatory framework
PART 17: Impact of drivers and challenges
PART 18: Market trends
- Advent of biosimilars expected to improve the treatment rates
- Outsourcing of biosimilar manufacturing activities
- High growth in the emerging markets
PART 19: Vendor landscape
- Competitive scenario
- Other prominent vendors
PART 20: Key vendor analysis
- F. Hoffmann-La Roche
- Amgen
- Johnson & Johnson
- Kyowa Hakko Kirin
PART 21: Appendix